Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

NCT07481357 is registered in ClinicalTrials.gov with Dong-A ST Co., Ltd. as lead sponsor.

NCT NCT07481357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07481357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
Lead sponsor
Dong-A ST Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 18, 2026
Completion date
February 28, 2029
Enrollment
51 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastric (stomach) cancer, gastroesophageal cancer, pancreatic ductal adenocarcinoma (mpdac)